• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰导管腺癌手术切除的 3 年和 5 年结果:一家医疗中心的长期经验。

Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center.

机构信息

Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

出版信息

Asian J Surg. 2018 Mar;41(2):115-123. doi: 10.1016/j.asjsur.2016.11.009. Epub 2016 Dec 20.

DOI:10.1016/j.asjsur.2016.11.009
PMID:28010955
Abstract

OBJECTIVE

Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study evaluated the 3-year and 5-year surgical outcomes associated with the cancer and determined whether statistically identified factors can be used to predict survival.

METHODS

This retrospective review was conducted from 1995 to 2010. Patients who had resectable pancreatic ductal adenocarcinoma and received surgical treatment were included. Cases of hospital mortality were excluded. The relationships between several clinicopathological factors and the survival rate were analyzed.

RESULTS

A total of 223 patients were included in this study. The 3-year and 5-year survival rates were 21.4% and 10.1%, respectively, and the median survival was 16.1 months. Tumor size, N status, and resection margins were independent predictive factors for 3-year survival. Tumor size independently predicted 5-year survival.

CONCLUSION

Tumor size is the most important independent prognostic factor for 3-year and 5-year survival. Lymph node status and the resection margins also independently affected the 3-year survival. These patient outcomes might be improved by early diagnosis and radical resection. Future studies should focus on the tumor biology of this aggressive cancer.

摘要

目的

胰腺导管腺癌是最恶性的癌症类型之一。本研究评估了与癌症相关的 3 年和 5 年手术结果,并确定是否可以使用统计学确定的因素来预测生存率。

方法

这是一项回顾性研究,时间为 1995 年至 2010 年。纳入接受手术治疗的可切除胰腺导管腺癌患者。排除住院死亡病例。分析了几种临床病理因素与生存率之间的关系。

结果

本研究共纳入 223 例患者。3 年和 5 年生存率分别为 21.4%和 10.1%,中位生存期为 16.1 个月。肿瘤大小、N 状态和切缘是 3 年生存率的独立预测因素。肿瘤大小独立预测 5 年生存率。

结论

肿瘤大小是 3 年和 5 年生存率的最重要独立预后因素。淋巴结状态和切缘也独立影响 3 年生存率。通过早期诊断和根治性切除,这些患者的结局可能会得到改善。未来的研究应集中在这种侵袭性癌症的肿瘤生物学上。

相似文献

1
Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center.胰导管腺癌手术切除的 3 年和 5 年结果:一家医疗中心的长期经验。
Asian J Surg. 2018 Mar;41(2):115-123. doi: 10.1016/j.asjsur.2016.11.009. Epub 2016 Dec 20.
2
Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.新辅助治疗后中性粒细胞与淋巴细胞比值升高与临界可切除性胰腺导管腺癌切除术后较差的生存率相关。
Surgery. 2016 Nov;160(5):1288-1293. doi: 10.1016/j.surg.2016.04.039. Epub 2016 Jul 20.
3
Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.胰腺导管腺癌的全胰切除术:美国国立癌症数据库综述
HPB (Oxford). 2016 Jan;18(1):21-8. doi: 10.1016/j.hpb.2015.07.009. Epub 2015 Dec 21.
4
Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study.早期胰腺导管腺癌的胰体尾切除术:一项单中心病例对照研究
Langenbecks Arch Surg. 2019 Mar;404(2):175-182. doi: 10.1007/s00423-019-01766-1. Epub 2019 Mar 2.
5
Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.胰体尾癌胰十二指肠切除术中术中输血的不良肿瘤学影响:严格输血政策的必要性
J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):497-507. doi: 10.1002/jhbp.368. Epub 2016 Jul 24.
6
Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.胰腺体积是可切除性胰腺导管腺癌的独立预后因素之一。
J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):472-9. doi: 10.1002/jhbp.365. Epub 2016 Jul 15.
7
Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study.胰腺导管内乳头状黏液性肿瘤行胰十二指肠切除术中肠系膜上静脉-门静脉切除的预后:一项前瞻性对照研究结果
Langenbecks Arch Surg. 2014 Jun;399(5):659-65. doi: 10.1007/s00423-014-1194-6. Epub 2014 Apr 30.
8
Clinical characteristics and overall survival in patients with anaplastic pancreatic cancer.间变性胰腺癌患者的临床特征与总生存期
Am Surg. 2014 Feb;80(2):117-23.
9
Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.胰腺腺癌切除术后长期预后的改善:两个时间段的比较。
Ann Surg Oncol. 2015 Apr;22(4):1160-7. doi: 10.1245/s10434-014-4196-2. Epub 2014 Oct 28.
10
Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.根治性手术切除后可切除性胰腺导管腺癌患者早期复发的术前危险因素。
Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7.

引用本文的文献

1
A machine learning model based on preoperative multiparametric quantitative DWI can effectively predict the survival and recurrence risk of pancreatic ductal adenocarcinoma.基于术前多参数定量扩散加权成像的机器学习模型能够有效预测胰腺导管腺癌的生存及复发风险。
Insights Imaging. 2025 Feb 17;16(1):38. doi: 10.1186/s13244-025-01915-9.
2
Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma.吉西他滨联合S-1新辅助化疗用于可切除胰腺导管腺癌的益处
Mol Clin Oncol. 2024 Dec 12;22(2):18. doi: 10.3892/mco.2024.2813. eCollection 2025 Feb.
3
Surgeon's Experience May Circumvent Operative Volume in Improving Early Outcomes After Pancreaticoduodenectomy.
在改善胰十二指肠切除术后的早期结局方面,外科医生的经验可能会弥补手术量的影响。
Cureus. 2023 Aug 3;15(8):e42927. doi: 10.7759/cureus.42927. eCollection 2023 Aug.
4
Outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing robotic (RPD) or open pancreaticoduodenectomies (OPD): a propensity score-weighted survival analysis.接受机器人(RPD)或开放胰十二指肠切除术(OPD)的胰腺导管腺癌(PDAC)患者的结局:倾向评分加权生存分析。
J Robot Surg. 2023 Jun;17(3):1085-1096. doi: 10.1007/s11701-022-01510-w. Epub 2022 Dec 30.
5
Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms.神经内分泌肿瘤患者自杀筛查评分的制定与验证
Front Psychiatry. 2021 Jun 11;12:638152. doi: 10.3389/fpsyt.2021.638152. eCollection 2021.
6
The experience of the minimally invasive (MI) fellowship-trained (FT) hepatic-pancreatic and biliary (HPB) surgeon: could the outcome of MI pancreatoduodenectomy for peri-ampullary tumors be better than open?微创(MI) fellowship 培训(FT)的肝胰和肝胆(HPB)外科医生的经验:经 MI 胰十二指肠切除术治疗壶腹周围肿瘤的结果是否优于开放手术?
Surg Endosc. 2021 Sep;35(9):5256-5267. doi: 10.1007/s00464-020-08118-x. Epub 2020 Nov 4.
7
The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data.基于真实世界数据的胰腺导管腺癌实际 5 年幸存者。
Sci Rep. 2020 Oct 2;10(1):16425. doi: 10.1038/s41598-020-73525-y.
8
MicroRNA-663 antagonizes apoptosis antagonizing transcription factor to induce apoptosis in epithelial cells.miRNA-663 拮抗凋亡抑制转录因子诱导上皮细胞凋亡。
Apoptosis. 2019 Feb;24(1-2):108-118. doi: 10.1007/s10495-018-01513-9.
9
Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancer.超声和近红外荧光成像引导腹腔镜分期探查胰腺和壶腹周围癌隐匿性转移。
PLoS One. 2018 Nov 1;13(11):e0205960. doi: 10.1371/journal.pone.0205960. eCollection 2018.
10
CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.CD44可预测接受根治性手术的胰腺癌患者的早期复发。
In Vivo. 2018 Nov-Dec;32(6):1533-1540. doi: 10.21873/invivo.11411.